Similar long-term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV-1-infected patients in a retrospective, real-life cohort of 14 years-Reference-Cited by-同舟云学术

Similar long-term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV-1-infected patients in a retrospective, real-life cohort of 14 years

Published:2018-07-03 Issue:9 Volume:19 Page:662-667
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Krznaric I¹,Bickel M²,Carganico A¹,De Leuw P³,Haberl A³,Knecht G²,Koegl C⁴,Lauscher P⁴,Schüttfort G³,Stephan C³,Wolf E⁴,Wolf T³^ORCID

Affiliation:

1. Centre for Infectious Diseases; Berlin Germany

2. Infektiologikum (Centre for Infectious Diseases) Frankfurt; Frankfurt Germany

3. Infectious Diseases Division; Department of Internal Medicine II; HIV Center; University Hospital Frankfurt; Frankfurt Germany

4. MUC Research; Munich Germany

Funder

Merck-Sharp Dome

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12636/fullpdf

Reference9 articles.

1. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials;Eron;Lancet Infect Dis,2013

2. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials;Eron;Lancet,2010

3. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial;Gallien;J Antimicrob Chemother,2011

5. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir;Blanco;Antivir Ther,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of protease inhibitor‐based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART‐naïve patients with HIV‐infection;HIV Medicine;2020-12-17

2. Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients;Antiviral Therapy;2019